176 related articles for article (PubMed ID: 25497488)
1. Particle engineering to enhance or lessen particle uptake by alveolar macrophages and to influence the therapeutic outcome.
Patel B; Gupta N; Ahsan F
Eur J Pharm Biopharm; 2015 Jan; 89():163-74. PubMed ID: 25497488
[TBL] [Abstract][Full Text] [Related]
2. Nano- and micro-based inhaled drug delivery systems for targeting alveolar macrophages.
Lee WH; Loo CY; Traini D; Young PM
Expert Opin Drug Deliv; 2015 Jun; 12(6):1009-26. PubMed ID: 25912721
[TBL] [Abstract][Full Text] [Related]
3. The application of high-content analysis in the study of targeted particulate delivery systems for intracellular drug delivery to alveolar macrophages.
Lawlor C; O'Sullivan MP; Sivadas N; O'Leary S; Gallagher PJ; Keane J; Cryan SA
Mol Pharm; 2011 Aug; 8(4):1100-12. PubMed ID: 21591762
[TBL] [Abstract][Full Text] [Related]
4. Liposome-based drug delivery to alveolar macrophages.
Vyas SP; Khatri K
Expert Opin Drug Deliv; 2007 Mar; 4(2):95-9. PubMed ID: 17335407
[TBL] [Abstract][Full Text] [Related]
5. Actin plays a crucial role in the phagocytosis and biological response to respirable quartz particles in macrophages.
Haberzettl P; Duffin R; Krämer U; Höhr D; Schins RP; Borm PJ; Albrecht C
Arch Toxicol; 2007 Jul; 81(7):459-70. PubMed ID: 17375287
[TBL] [Abstract][Full Text] [Related]
6. Targeting to macrophages: role of physicochemical properties of particulate carriers--liposomes and microspheres--on the phagocytosis by macrophages.
Ahsan F; Rivas IP; Khan MA; Torres Suarez AI
J Control Release; 2002 Feb; 79(1-3):29-40. PubMed ID: 11853916
[TBL] [Abstract][Full Text] [Related]
7. Inhaled Solid Lipid Microparticles to target alveolar macrophages for tuberculosis.
Maretti E; Rossi T; Bondi M; Croce MA; Hanuskova M; Leo E; Sacchetti F; Iannuccelli V
Int J Pharm; 2014 Feb; 462(1-2):74-82. PubMed ID: 24374224
[TBL] [Abstract][Full Text] [Related]
8. Particulate systems for targeting of macrophages: basic and therapeutic concepts.
Moghimi SM; Parhamifar L; Ahmadvand D; Wibroe PP; Andresen TL; Farhangrazi ZS; Hunter AC
J Innate Immun; 2012; 4(5-6):509-28. PubMed ID: 22722900
[TBL] [Abstract][Full Text] [Related]
9. Physicochemical and biological aspects of macrophage-mediated drug targeting in anti-microbial therapy.
Kunjachan S; Jose S; Thomas CA; Joseph E; Kiessling F; Lammers T
Fundam Clin Pharmacol; 2012 Feb; 26(1):63-71. PubMed ID: 21631585
[TBL] [Abstract][Full Text] [Related]
10. One-step preparation of rifampicin/poly(lactic-co-glycolic acid) nanoparticle-containing mannitol microspheres using a four-fluid nozzle spray drier for inhalation therapy of tuberculosis.
Ohashi K; Kabasawa T; Ozeki T; Okada H
J Control Release; 2009 Apr; 135(1):19-24. PubMed ID: 19121349
[TBL] [Abstract][Full Text] [Related]
11. Influence of particle geometry and PEGylation on phagocytosis of particulate carriers.
Mathaes R; Winter G; Besheer A; Engert J
Int J Pharm; 2014 Apr; 465(1-2):159-64. PubMed ID: 24560647
[TBL] [Abstract][Full Text] [Related]
12. Mannosylated nanoparticulate carriers of rifabutin for alveolar targeting.
Nimje N; Agarwal A; Saraogi GK; Lariya N; Rai G; Agrawal H; Agrawal GP
J Drug Target; 2009 Dec; 17(10):777-87. PubMed ID: 19938949
[TBL] [Abstract][Full Text] [Related]
13. Metal Organic Framework (MOF) Particles as Potential Bacteria-Mimicking Delivery Systems for Infectious Diseases: Characterization and Cellular Internalization in Alveolar Macrophages.
Guo A; Durymanov M; Permyakova A; Sene S; Serre C; Reineke J
Pharm Res; 2019 Feb; 36(4):53. PubMed ID: 30790066
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic aerosol bioengineering of siRNA for the treatment of inflammatory lung disease by TNFα gene silencing in macrophages.
Kelly C; Yadav AB; Lawlor C; Nolan K; O'Dwyer J; Greene CM; McElvaney NG; Sivadas N; Ramsey JM; Cryan SA
Mol Pharm; 2014 Nov; 11(11):4270-9. PubMed ID: 25243784
[TBL] [Abstract][Full Text] [Related]
15. Distribution and Cellular Uptake of PEGylated Polymeric Particles in the Lung Towards Cell-Specific Targeted Delivery.
Shen TW; Fromen CA; Kai MP; Luft JC; Rahhal TB; Robbins GR; DeSimone JM
Pharm Res; 2015 Oct; 32(10):3248-60. PubMed ID: 26002743
[TBL] [Abstract][Full Text] [Related]
16. Macrophage-specific targeting of isoniazid through mannosylated gelatin microspheres.
Tiwari S; Chaturvedi AP; Tripathi YB; Mishra B
AAPS PharmSciTech; 2011 Sep; 12(3):900-8. PubMed ID: 21732158
[TBL] [Abstract][Full Text] [Related]
17. Shielding Therapeutic Drug Carriers from the Mononuclear Phagocyte System: A Review.
Sathyamoorthy N; Dhanaraju MD
Crit Rev Ther Drug Carrier Syst; 2016; 33(6):489-567. PubMed ID: 27992308
[TBL] [Abstract][Full Text] [Related]
18. PEG-PLGA based large porous particles for pulmonary delivery of a highly soluble drug, low molecular weight heparin.
Patel B; Gupta V; Ahsan F
J Control Release; 2012 Sep; 162(2):310-20. PubMed ID: 22800582
[TBL] [Abstract][Full Text] [Related]
19. Delivery strategies for sustained drug release in the lungs.
Loira-Pastoriza C; Todoroff J; Vanbever R
Adv Drug Deliv Rev; 2014 Aug; 75():81-91. PubMed ID: 24915637
[TBL] [Abstract][Full Text] [Related]
20. Delivery of ofloxacin to the lung and alveolar macrophages via hyaluronan microspheres for the treatment of tuberculosis.
Hwang SM; Kim DD; Chung SJ; Shim CK
J Control Release; 2008 Jul; 129(2):100-6. PubMed ID: 18538437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
